Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28561387 | 0.98 | SLC6A4 (0.30) | SLC6A4SLC6A3 | |
| Hydrochloric Acid SCHEMBL10326142 | 0.98 | SLC6A4 (0.30) | SLC6A4SLC6A3 | |
| SCHEMBL23034417 | 0.97 | — | — | |
| SCHEMBL35605 | 0.97 | — | — | |
| SCHEMBL31274088 | 0.97 | — | — | |
| SCHEMBL3411687 | 0.95 | SLC6A4 (0.31) | SLC6A4SLC6A3 | |
| SCHEMBL284166 | 0.95 | SLC6A4 (0.31) | SLC6A4SLC6A3 | |
| Bromide SCHEMBL14876845 | 0.95 | SLC6A4 (0.31) | SLC6A4SLC6A3 | |
| Hydrochloric Acid SCHEMBL1790308 | 0.95 | SLC6A4 (0.31) | SLC6A4SLC6A3 | |
| Iodide SCHEMBL14877122 | 0.95 | SLC6A4 (0.31) | SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 204 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118290713-A | Preparation method and application of NNO (N-phenylene-imine) lactide ring-opening polymerization catalyst | 吉林大学 | 2024-07-05 | — | — | CN | claimed |
| CN-115894884-B | Trifunctional organic catalyst and preparation method and application thereof | 浙江大学 | 2024-07-05 | — | — | CN | claimed |
| CN-117377660-A | Process for the preparation of benzoxazepine oxazolidinone compounds | 基因泰克公司 | 2024-01-09 | — | — | CN | claimed |
| CN-116056708-A | Process for preparing WEE1 inhibitor compounds | 里科瑞尔姆IP控股有限责任公司 | 2023-05-02 | — | — | CN | claimed |
| CN-115894884-A | Trifunctional organic catalyst, and preparation method and application thereof | 浙江大学 | 2023-04-04 | — | — | CN | claimed |
| CN-115181114-A | Preparation method of thiazolidone-containing tricyclic compound | 江苏豪森药业集团有限公司 | 2022-10-14 | — | — | CN | claimed |
| CN-115124491-A | Preparation method of cyclododecane oxide and cyclododecanone | 中国科学院上海有机化学研究所 | 2022-09-30 | — | — | CN | claimed |
| CN-112409355-B | Preparation method of apixaban | 南京法恩化学有限公司 | 2022-04-05 | — | — | CN | claimed |
| CN-114210363-A | Preparation method of SSZ-16 copper-containing catalyst | 天津派森新材料技术有限责任公司 | 2022-03-22 | — | — | CN | claimed |
| CN-113582902-A | Preparation method of brivaracetam and intermediate thereof | 浙江华海药业股份有限公司 | 2021-11-02 | — | — | CN | claimed |
| CN-113462375-A | Chemical intervention in-situ emulsification system | 西南石油大学 | 2021-10-01 | — | — | CN | claimed |
| CN-110088111-B | Preparation method of (S) -2- ((2- ((S) -4- (difluoromethyl) -2-oxooxazolidin-3-yl) -5, 6-dihydrobenzo [ f ] imidazo [1,2-d ] [1,4] oxazepin-9-yl) amino) propionamide | 豪夫迈·罗氏有限公司 | 2021-08-03 | — | — | CN | claimed |
| CN-112939829-A | Synthetic method of aryl trifluoromethyl thioether | 武汉药明康德新药开发有限公司 | 2021-06-11 | — | — | CN | claimed |
| CN-110204493-B | Tricyclic XOR inhibitor and preparation method and application thereof | 华南理工大学 | 2021-05-14 | — | — | CN | claimed |
| CN-112409355-A | Preparation method of apixaban | 南京法恩化学有限公司 | 2021-02-26 | — | — | CN | claimed |
| CN-111848322-A | Axial chiral oxindole-substituted styrene compound and resolution method and application thereof | 江苏师范大学 | 2020-10-30 | — | — | CN | claimed |
| CN-102234234-A | Method for synthesizing (1R,2R)-(-)-N,N-dimethyl-1,2-cyclohexanediamine oxalate | WUXI APPTEC CO LTD | 2011-11-09 | — | — | CN | claimed |
| CN-101010309-A | Oxopiperidine derivatives, preparation and therapeutic use thereof | SANOFI AVENTIS (FR) | 2007-08-01 | — | — | CN | claimed |
| US-20240239811-A1 | 5-(5-(PIPERIDIN-4-YL)THIENO[3,2-C]PYRAZOL-2-YL]INDAZOLE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS FOR SPLICING NUCLEIC ACIDS AND FOR THE T | REMIX THERAPEUTICS INC. | 2024-07-18 | — | — | US | disclosed |
| WO-2002085838-A1 | COPPER-CATALYZED FORMATION OF CARBON-HETEROATOM AND CARBON-CARBON BONDS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2002-10-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239811-A1 | 5-(5-(PIPERIDIN-4-YL)THIENO[3,2-C]PYRAZOL-2-YL]INDAZOLE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS FOR SPLICING NUCLEIC ACIDS AND FOR THE T | HNRNPAB, HNRNPC, HNRNPA1 | SLC6A4 3275/4885SLC6A3 3707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.